Sound waves and a drug team up to fight brain tumors

NCT ID NCT07076472

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment for glioblastoma that has come back or is getting worse. The therapy combines a drug called 5-ALA with focused ultrasound waves to target and kill tumor cells without surgery. Eight adults with recurrent glioblastoma will receive the treatment to find the safest dose and see if it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aminolevulinic acid hydrochloride (5-ALA HCl) combined with focused ultrasound
What this could lead to: If it works, this could point toward a new non-invasive treatment option for recurrent glioblastoma that may slow tumor growth.
What could go wrong: This is a very early, small pilot study with only 8 participants, so results may not apply broadly. The treatment may not be effective or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE GLIOBLASTOMA RECURRENT GLIOBLASTOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.